Evaxion Shares Jump on Positive Melanoma Vaccine Trial Data

By EC Assets · Published 19 October 2026

Evaxion AS ADR shares surged following the announcement of three-year melanoma vaccine trial data. The stock increase occurred on October 19, 2026. Evaxion's stock climbed 21.6%. Evaxion specializes in developing AI-Immunology powered vaccines. The company is a clinical-stage TechBio firm. Its AI-Immunology platform applies to glioblastoma, integrating both neoantigens and endogenous retroviruses as antigen targets for vaccine design. Evaxion intends to seek partnerships for the glioblastoma vaccine. The company plans to present two-year clinical efficacy data from a phase 2 trial of its AI-designed personalized cancer vaccine EVX-01. This presentation is scheduled for the ESMO Congress in 2025. Evaxion will present these results in Copenhagen, Denmark. The announcement for this presentation was made on July 25, 2025. Evaxion trades under the NASDAQ ticker EVAX. The company's full name is Evaxion A/S. Luke Juricic authored the Investing.com report on the stock surge. The report was published on October 19, 2026, at 12:28 PM. This article is intended for informational purposes only. It does not constitute investment advice.